Investors

Stock
Information

MEDINCELL EURONEXT ELIGIBLE PME PEA

Listed on
EURONEXT PARIS / B COMPARTMENT
ISIN code / Ticker
FR0004065605 / MEDCL
Number of shares (May 31, 2022)
25,143,553
Liquidity Provider
KEPLER CHEUVREUX
Analysts
BRYAN GARNIER & CO
KEPLER CHEUVREUX
ODDO-BHF

Download our latest corporate presentation

Share price 06.07.2022 | 15:25 (Paris time)
4.975 €-1.29%
Opening5.04 €
Previous closing 5.04 €
Shares traded 8.96 k

Investors

Events &
Presentations

June 14, 2022

MedinCell
Annual results 2021-2022 (Apr. 2021 > Mar. 2022)

Add to calendar

September 08, 2022

MedinCell
2022 General Meeting

Add to calendar

December 06, 2022

MedinCell
Half-Year results
(Apr. > Sept. 2022)

Add to calendar

Download calendar

PREVIOUS EVENTS

June 14, 2022

Videoconference • Annual results 2021-202

Replay

Transcript Presentation

December 08, 2021

Videoconference • Half Year results

Replay

Transcript Presentation

November 02, 2021

Videoconference • mdc-IRM Phase 3 results

Replay

Transcript

September 01, 2021

Video conference • Portfolio update

Replay

Transcript Presentation

June 16, 2021

Video Conference • Annual results

Replay

Transcript Presentation

December 09, 2020

Video Conference • Half year results

Replay

Transcript

June 04, 2020

Video Conference • Annual results

Replay

Transcript

April 23, 2020

Video Conference • Adapt and overcome to the Covid-19 crisis

Replay

Transcript Presentation

December 03, 2019

Audio conference • Half year results

Replay

Transcript Presentation

June 04, 2019

Audio Conference • Annual results

Replay

Transcript Presentation

December 03, 2018

Audio Conference • Half year results

Replay

Transcript Presentation

See all

Session en français

Rendez-vous le mardi 14 juin à 18h30 (CEST) pour une vidéoconférence dédiée aux résultas annuel 2021-2022

English session

On Tuesday 14, June at 7.30 pm (CEST) participate in our videoconference dedicated to our Financial year 2021-2022 results

INVESTORS

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

Investors

Documentation

Regulated informations

Jan. 2022 Half-year liquidity contract statement

Dec. 2021 Half-Year report (French)

URD 2020/2021 (French)

See all

July 2021 Half-year liquidity contract statement

Jan. 2021 Half-year liquidity contract statement

Dec. 2020 Half year report (French)

URD 2019/2020 (French)

July 2020 Half-year liquidity contract statement

Jan. 2020 Half-year liquidity contract statement

Jan. 2020 Half-Year liquidity contract report (French)

Dec. 2019 Half year report (French)

2018/2019 Annual financial report (French)

July 2019 Half year liquidity contract (French)

Dec. 2018 Half year report (French)

International Offering Memorandum (Sept. 14 2018)

Shares & Voting rights

May 31, 2022 (French)

April 30, 2022 (French)

March 31, 2022 (French)

See all

February 28, 2022 (French)

January 31, 2022 (French)

December 31, 2021 (French)

November 30, 2021 (French)

October 31, 2021 (French)

September 30, 2021 (French)

August 31, 2021 (French)

July 31, 2021 (French)

May 31, 2021 (French)

April 30, 2021 (French)

March 31, 2021 (French)

February 28, 2021 (French)

January 31, 2021 (French)

December 31, 2020 (French)

October 31, 2020 (French)

September 30, 2020 (French)

August 31, 2020 (French)

July 31, 2020 (French)

June 30, 2021 (French)

June 30, 2020 (French)

May 31, 2020 (French)

Avril 30, 2020 (French)

March 31, 2020 (French)

February 29, 2020 (French)

January 31, 2020 (French)

December 31, 2019 (French)

November 30, 2019 (French)

October 31, 2019 (French)

September 30, 2019 (French)

August 31, 2019 (French)

July, 31, 2019 (French)

June 30, 2019 (French)

May 31, 2019 (French)

April 30, 2019 (French)

March 31, 2019 (French)

February 28, 2019 (French)

January 31, 2019 (French)

December 31, 2018 (French)

November 30, 2018 (French)

October 31, 2018 (French)

Investors

General
Meeting

September 2021
September 2020
December 2020
September 2019

September 2021

> Voting results (French) > Meeting Brochure (French) > Unique participation form > Voting rights as August 4, 2021 (French) > Special report of the statutory auditors on regulated agreements (French) > Statutory auditors’ report on the consolidated financial statements (French) > Statutory auditors’ report on the annual accounts (French) > Statutory auditors’ report on the capital reduction (French) > Statutory auditors’ report on the authorization to allocate free shares, existing or to be issued (French) > Statutory auditors’ report on the issue of shares and various securities with maintenance and / or cancellation of preferential subscription rights (French) > Statutory Auditors’ report on the capital increase reserved for members of a company savings plan (French) > Statutory Auditors’ Declaration on the highest paid individuals (French) > Text of resolutions (French) > Report of the management board to the ordinary annual and extraordinary general meeting (French) > Statutory Auditors’ report on the authorization to grant options to subscribe and / or purchase shares (French) > Convening notice (French) > URD 2020/2021 (French)

See all

> Supervisory board report (French) > Minutes of the General Meeting of September 10, 2020 (French) > Resolutions voting results (French) > Statutory auditors’ special report on regulated agreements (French) > Statutory Auditors’ report on the consolidated financial statements (French) > Statutory auditors’ report on the annual accounts (French) > Statutory Auditors’ report on the capital reduction (French) > Statutory Auditors’ report on the issue of shares and various securities with maintenance and / or cancellation of preferential subscription rights (French) > Statutory auditors’ report on the issue of warrants with cancellation of preferential subscription rights (French) > Statutory Auditors’ report on the authorization to grant share subscription and / or purchase options (French) > Statutory auditors’ report on the capital increase reserved for members of a company savings plan (French) > Statutory Auditors’ report on the authorization to allocate free shares, existing or to be issued (French) > General Meeting notice (French) > Report of the Diretoire to the Annual Ordinary and Extraordinary General Meeting of September 10, 2020 (French) > Individual identity card – Sabri Markabi (French) > Summary of activities (French) > Voting rights as of July 31 2020 (French) > General meeting notice (French) > Unique participation form > Resolutions (French) > URD 2019/2020 (French)

See all

> Minutes of the General Meeting of December 15, 2020 (French) > Convening notice (French) > Management Board report (French) > Unique participation form > Status (French) > Resolutions (French) > General meeting notice (French) > Voting rights as of November 9 2020 (French)

See all

> Resolutions voting results (French) > Minutes of the General Meeting of September 5, 2019 (French) > Statutory auditors’ special report on regulated agreements (French) > Resolutions (in French) > Annual financial report (in French) > Statutory Auditors Fees (in French) > Composition of the Directoire (in French) > Composition of the Supervisory Board (in French) > Statutory auditors’ report on the decrease in common stock (in French) > Statutory auditors’ report on the issue of warrants with cancellation of preferential subscription rights (in French) > Statutory Auditors’ report on the capital increase for members of a Company saving plan (in French) > Statutory Auditors’ Declaration on the highest paid individuals (in French) > Corporate governance report – Report of the Supervisory Board (in French) > Statutory Auditors’ report on the consolidated financial statements (in French) > Directoire’s report (in French) > Statutory auditors’ report on the annual accounts (in French) > Unique participation form > General meeting notice (in French)

See all

Investors

Contacts

MedinCell

Head of Communication / IR

David Heuzé

david.heuze@medincell.com

+33 (0)6 83 25 21 86

MedinCell

Senior Communications Officer

Nicolas Gourgues

nicolas.gourgues@medincell.com

Investor Relations

NewCap

Louis-Victor Delouvrier & Mathilde Bohin

medincell@newcap.eu

+33 (0)1 44 71 94 94

Media

NewCap

Nicolas Merigeau

medincell@newcap.eu

+33 (0)1 44 71 94 94

CONTACT

  • This field is for validation purposes and should be left unchanged.